|
gptkbp:instanceOf
|
gptkb:company
|
|
gptkbp:CEO
|
gptkb:Pierre-Alain_Ruffieux
|
|
gptkbp:country
|
gptkb:Switzerland
|
|
gptkbp:focusArea
|
biologics
small molecules
cell and gene therapy
microbial control solutions
contract development and manufacturing organization (CDMO)
|
|
gptkbp:founded
|
1897
|
|
gptkbp:headquartersLocation
|
gptkb:Basel,_Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lonza
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:ISIN
|
CH0013841017
|
|
gptkbp:notableAcquisition
|
gptkb:Capsugel
gptkb:Bend_Research
gptkb:Cell_Therapy_Manufacturing_Facility_(Houston)
gptkb:Pharmalucence
|
|
gptkbp:numberOfEmployees
|
~17,000
|
|
gptkbp:products
|
biotechnology products
custom manufacturing
pharmaceutical ingredients
|
|
gptkbp:publiclyTraded
|
true
|
|
gptkbp:revenue
|
CHF 6.2 billion (2023)
|
|
gptkbp:stockExchange
|
gptkb:SIX_Swiss_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:LONN
|
|
gptkbp:subsidiary
|
gptkb:Capsugel
|
|
gptkbp:website
|
https://www.lonza.com/
|
|
gptkbp:bfsParent
|
gptkb:Genome_Valley
gptkb:Slough_Trading_Estate
gptkb:Fetal_Calf_Serum
|
|
gptkbp:bfsLayer
|
6
|